RETHYMIC Trademark
Trademark Overview
On Thursday, February 28, 2019, a trademark application was filed for RETHYMIC with the United States Patent and Trademark Office. The USPTO has given the RETHYMIC trademark a serial number of 88319658. The federal status of this trademark filing is REGISTERED as of Tuesday, April 7, 2020. This trademark is owned by Enzyvant Therapeutics GmbH. The RETHYMIC trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for human use for the treatment of pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; pharmaceutical preparations for human use, namely, tissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; biologic preparations for medical and therapeutic purposes for the treatment of pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; biologic preparations for medical and therapeutic purposes, namely, tissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto
General Information
| Serial Number | 88319658 |
| Word Mark | RETHYMIC |
| Filing Date | Thursday, February 28, 2019 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, April 7, 2020 |
| Registration Number | 6026670 |
| Registration Date | Tuesday, April 7, 2020 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, January 21, 2020 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for human use for the treatment of pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; pharmaceutical preparations for human use, namely, tissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; biologic preparations for medical and therapeutic purposes for the treatment of pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; biologic preparations for medical and therapeutic purposes, namely, tissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, March 19, 2019 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | SUMITOMO PHARMA CO., LTD. |
| Party Type | 32 - New Owner After Registration |
| Legal Entity Type | 99 - Other |
| Address | OSAKA 541-0045
JP |
| Party Name | SUMITOMO PHARMA SWITZERLAND GMBH |
| Party Type | 31 - New Owner After Registration |
| Legal Entity Type | 27 - NOT AVAILABLE |
| Address | BASEL 4051
CH |
| Party Name | Enzyvant Therapeutics GmbH |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | Basel 4051
CH |
| Party Name | Enzyvant Therapeutics GmbH |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Basel 4051
CH |
| Party Name | Enzyvant Therapeutics GmbH |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Basel 4051
CH |
Trademark Events
| Event Date | Event Description |
| Monday, March 4, 2019 | NEW APPLICATION ENTERED |
| Tuesday, March 19, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, May 9, 2019 | ASSIGNED TO EXAMINER |
| Sunday, May 19, 2019 | NON-FINAL ACTION WRITTEN |
| Sunday, May 19, 2019 | NON-FINAL ACTION E-MAILED |
| Sunday, May 19, 2019 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, July 25, 2019 | ASSIGNED TO EXAMINER |
| Saturday, November 9, 2019 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, November 9, 2019 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, November 11, 2019 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Sunday, December 1, 2019 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, December 4, 2019 | ASSIGNED TO LIE |
| Friday, December 6, 2019 | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED |
| Friday, December 13, 2019 | ELECTRONIC RECORD REVIEW COMPLETE |
| Wednesday, January 1, 2020 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, January 21, 2020 | PUBLISHED FOR OPPOSITION |
| Tuesday, January 21, 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, April 7, 2020 | REGISTERED-PRINCIPAL REGISTER |
| Monday, April 7, 2025 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| Wednesday, March 18, 2026 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Wednesday, April 1, 2026 | TEAS SECTION 8 & 15 RECEIVED |
| Wednesday, June 3, 2026 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
